New activity is brewing for Metsera, Inc. ( (MTSR) ). The company has submitted a Form DEFM14A to the SEC, indicating an upcoming shareholder vote. This form gives shareholders all the information they need to develop an informed vote. Read on to learn more about the proposed company action.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Metsera, Inc. has scheduled a special meeting for its stockholders on November 13, 2025, to vote on a proposed merger with Pfizer Inc. The merger agreement, dated September 21, 2025, outlines that Metsera will become a wholly-owned subsidiary of Pfizer. Stockholders will receive $47.50 in cash per share and a contingent value right for potential future payments. The Board of Directors of Metsera has unanimously recommended the approval of the merger, emphasizing its fairness and benefits to stockholders.
The most recent analyst rating on (MTSR) stock is a Hold with a $54.00 price target. To see the full list of analyst forecasts on Metsera, Inc. stock, see the MTSR Stock Forecast page.
Spark’s Take on MTSR Stock
According to Spark, TipRanks’ AI Analyst, MTSR is a Underperform.
Metsera, Inc. faces significant challenges, primarily due to its lack of revenue and ongoing financial losses, which are critical concerns for long-term viability. The technical analysis indicates bearish momentum, reinforcing negative sentiment. Valuation metrics are limited, as the company does not have earnings or dividends. Despite a strong cash position, the high cash burn rate poses a risk. Overall, the lack of revenue and negative technical indicators weigh heavily on the stock’s potential.
To see Spark’s full report on MTSR stock, click here.
More about Metsera, Inc.
Average Trading Volume: 2,116,266
Technical Sentiment Signal: Strong Buy
Current Market Cap: $5.55B
Learn more about MTSR stock on TipRanks’ Stock Analysis page.